Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 2 · 50%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Fixed‐dose combination aclidinium/formoterol vs placebo · Exacerbations requiring steroids or antibiotics or both: number of participants
  Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
  OR 0.82 [0.6, 1.12]
  2 studies · 1960 participants
  Moderate
Direct match · question page
- Umeclidinium bromide vs placebo · Number of participants with exacerbations requiring steroids, antibiotics, or both
  Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
  OR 0.61 [0.46, 0.8]
  4 studies · 1922 participants
  High
Direct match · question page
- Fixed‐dose combination aclidinium/formoterol vs aclidinium alone · Exacerbations requiring steroids or antibiotics or both: number of participants
  Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
  OR 0.95 [0.71, 1.27]
  2 studies · 2156 participants
  Moderate
Direct match · question page
- Fixed‐dose combination aclidinium/formoterol vs formoterol · Exacerbations requiring steroids or antibiotics or both: number of participants
  Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
  OR 0.78 [0.62, 0.99]
  3 studies · 2694 participants
  High

Fixed‐dose combination aclidinium/formoterol vs aclidinium alone

Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with aclidinium alone (moderate certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 0.95 [0.71, 1.27]
2 studies · 2156 participants
Moderate

Fixed‐dose combination aclidinium/formoterol vs placebo

Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with placebo (moderate certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 0.82 [0.6, 1.12]
2 studies · 1960 participants
Moderate

Fixed‐dose combination aclidinium/formoterol vs formoterol

Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol leads to lower exacerbations requiring steroids or antibiotics or both: number of… compared with formoterol (high certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 0.78 [0.62, 0.99]
3 studies · 2694 participants
High

Umeclidinium bromide vs placebo

Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease

Umeclidinium bromide leads to lower number of participants with exacerbations requiring steroids,… compared with placebo (high certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 0.61 [0.46, 0.8]
4 studies · 1922 participants
High